Clinical Trial Update: A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SHR3680 in metastatic castration-resistant prostate cancer across Phase 1 and Phase 2, with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-refractory Prostate Cancer
• Prostate Cancer

Drugs mentioned

• SHR3680

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN